Arvinas (ARVN) Income from Continuing Operations (2017 - 2026)
Arvinas (ARVN) recorded quarterly Income from Continuing Operations of 57600000.0 in Q1 2026, up 14.54% quarter-over-quarter from 67400000.0 in Q4 2025, and down 169.48% on a YoY basis from 82900000.0 in Q1 2025.
Arvinas (ARVN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Arvinas' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 57600000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 169.48% year-over-year to 57600000.0; the TTM figure through Mar 2026 stood at 221300000.0 (down 374.89% YoY), while the FY2025 annual figure was 80800000.0, up 59.38% from the prior year.
- Income from Continuing Operations was 57600000.0 for Q1 2026 at Arvinas, up from 67400000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 82900000.0 in Q1 2025 to a low of 154800000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 57300000.0 across 5 years, with a median of 63300000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations soared 219.45% in 2025, then sank 169.48% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 80100000.0 in 2022, then plunged by 93.26% to 154800000.0 in 2023, then jumped by 70.87% to 45100000.0 in 2024, then slumped by 49.45% to 67400000.0 in 2025, then advanced by 14.54% to 57600000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 57600000.0 (Q1 2026), 67400000.0 (Q4 2025), and 35100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -57.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |
| Jun 30, 2021 | -50.30 Mn |